The Experts Discuss: Vitamin K2 Going Mass Market - Successful Product Launches
The unparalleled bone and heart benefits of vitamin K2 MK-7 have opened doors to mass market consumers. More and more K2 products are being launched, with companies and marketers looking to gain first-mover advantage.
Join Kappa Bioscience and a panel of industry experts who will discuss and answer questions about launching successful K2 products.
K2 is ready for mass markets. Join us to learn how to profit from the enormous potential of vitamin K2 MK-7
The origin of K2VITAL® dates back to 2006, when Norwegian researcher, Dr Inger Reidun Aukrust, together with her team, discovered a process to produce all-trans Vitamin K2, MK-7, using natural compounds such as geraniol and farnesol in a strictly controlled synthesis process. The significance of the process for all-trans vitamin K2 MK-7 has been recognised and patented. For vitamin K’s, two stereo chemical versions can exist: cis and trans forms of the molecule. The cis form remains biologically inactive, while the trans form has a full biological potential.
The Kappa portfolio of premium ingredients represents a team of Superheroes for the bone and heart dietary supplements health categories.
Kappa deeply believes in the promise of vitamin K2 MK-7 and has a mission to improve health and well-being globally. Kappa developed the K2 Academy as a learning center on all facets of vitamin K2, from history to health, manufacturing to final formulation. The Academy includes a range of tools in a variety of formats educate new distributors, customers and the public on the promise of K2VITAL®.